Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab

The study evaluated the impact of subcutaneous trastuzumab on health-related quality of life (HRQoL) in 163 patients with HER2-overexpressing breast cancer. It found that subcutaneous trastuzumab improved certain symptoms, such as reducing nausea and vomiting, and did not negatively affect most functional scales, although it was associated with worse cognitive function and dyspnea. Patients receiving more than 8 cycles reported fewer side effects. In metastatic cases, subcutaneous trastuzumab did not negatively impact HRQoL and was preferred over intravenous administration due to reduced healthcare costs and patient preference. The study emphasized the favorable profile of subcutaneous trastuzumab, particularly in reducing chemotherapy-related side effects, but noted that further studies are needed due to its observational nature and small sample size.